Scopus Biopharma's (NASDAQ: SCPS) share price has rocketed on Monday after the company announced the approval of an investigational new drug application (IND) by the United States Food and Drug Administration (FDA).
The approval is for the biopharmaceutical company's lead drug candidate, CpG-STAT3siRNA, an immuno-oncology RNA therapy for the treatment of multiple cancers.
A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will now be initiated by Scopus at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases.
Scopus Biopharma's stock price had been trading around the $5 level since early May but has today run to highs of $19.95. It is currently trading at $15.26, up 156% from Friday's close of $5.96.
Should You Invest in Scopus Biopharma Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now